BCL2 and metastatic prostate carcinoma: Docetaxel is used to treat metastatic prostate cancer and exerts its activity through stabilization of microtubules and induction of BCL-2 phosphorylation, resulting in G2/M arrest, mitotic catastrophe, and apoptosis [24].